A major element driving market expansion is the rising need for innovative tissue transplantation products and organ transplantation to treat organ failure. Organ failure can be caused by several reasons, including severe trauma, poor eating habits, excessive alcohol intake, poisoning, blood loss, drug misuse, and other acute disorders. Diabetes and high blood pressure, for example, are the most common causes of end-stage kidney disease, which requires a renal transplant or dialysis to keep a patient alive. The need for tissue and organ transplantation, particularly kidney, heart, liver, and lungs transplantation, is quite high worldwide. In 2019, around 122,913 people were waiting for organ transplants in the United States, according to the US Department of Health and Human Services.
The market is also being boosted by the launch of technologically improved products and an increase in the number of tissue banks. According to the US Department of Health and Human Services, 43,201 people in the US were waiting for kidney transplants in 2019, although only 23,401 kidney transplants were carried out. Furthermore, recipients are prescribed potent immunosuppressive medicines following transplantation surgery, increasing their susceptibility to infectious infections as their immune is reduced. Technological advancements in novel transplant products and methods by biotechnology and medical device companies and rising healthcare spending are expected to boost the market.
Another factor driving the market is an increase in the prevalence of acute diseases like diabetes and high blood pressure that lead to end-stage renal disease. According to the World Health Organization (WHO), the geriatric population will exceed 2 billion by 2050. Liver, lung and kidney failures, cardiovascular illnesses, and other conditions are becoming increasingly common as a result of the rising prevalence of chronic diseases. This is a significant factor driving organ care product demand. Cirrhosis is the eleventh largest cause of death globally, and liver cancer is the sixteenth leading cause of death, according to the European Association for the Study of Liver.
However, limitations, such as a scarcity of organ donors for transplantation and high costs, are projected to limit market expansion. The need for organ care is being hampered by the high expense of therapy. The lengthy clearance process for novel organ care products hinders the organ care market's growth. The market's expansion is being hampered by a scarcity of trained specialists in the organ care system. Transplanting a human organ is a very sophisticated surgery requiring outstanding abilities. Because there are so few surgeons in this field who can perform these types of procedures, the cost of this procedure is extremely high. This aspect can potentially stifle the expansion of the organ transplantation market significantly. Furthermore, the number of organ donors is insignificant compared to the number of persons who require such organs. Another key aspect that may stymie the expansion of the organ transplantation market is the rising incidence of organ failure.
In December 2021, Penn Medicine announced that it had received a seven-year, $14 million grant from the National Institutes of Health (NIH) to apply chimeric antigen receptor T-cell immunotherapies to identify and treat patients in need of kidney transplants. OrganOx Limited debuted its ground-breaking liver perfusion equipment in January 2019. It was also given the green light by the UK's National Institute for Health and Care Excellence.
The tissue products category is expected to dominate the market. The segment's growth is fueled by rising demand for transplant operations such as cochlear implants, orthopedic soft tissues, heart valves, and bone marrow.
Renal or kidney transplantation is the most prevalent type of organ transplantation worldwide. Although various treatments for end-stage renal disease, such as dialysis, are available, kidney transplantation is widely regarded as the best option.
The hospital's category accounted for the greatest proportion owing to the significant number of organ and tissue transplant procedures performed at hospitals. However, due to the rising demand for healthcare facilities that cater to patients' unmet requirements and government programs encouraging organ donation, the transplant centers category is likely to increase over the projection period.
Over the projected period, the Asia Pacific region is expected to grow at the highest rate. The developing medical tourism in Asia Pacific countries such as India, the growing geriatric population in various nations, and the rising prevalence of congenital hydrocephalus in China are all factors driving revenue growth in this regional market.
Access to solid organ transplantation has been hampered by the COVID-19 epidemic. During the epidemic, the number of transplants performed decreased globally. The most afflicted organ transplants were kidneys, followed by the lungs, liver, and heart. COVID-19 had a global impact on transplantation, with a 31% decline in solid organ transplants conducted during the first pandemic wave compared to the previous year. Approximately 48,000 years of patient life were lost as a result of this deterioration.
The market is also being boosted by the launch of technologically improved products and an increase in the number of tissue banks. According to the US Department of Health and Human Services, 43,201 people in the US were waiting for kidney transplants in 2019, although only 23,401 kidney transplants were carried out. Furthermore, recipients are prescribed potent immunosuppressive medicines following transplantation surgery, increasing their susceptibility to infectious infections as their immune is reduced. Technological advancements in novel transplant products and methods by biotechnology and medical device companies and rising healthcare spending are expected to boost the market.
Another factor driving the market is an increase in the prevalence of acute diseases like diabetes and high blood pressure that lead to end-stage renal disease. According to the World Health Organization (WHO), the geriatric population will exceed 2 billion by 2050. Liver, lung and kidney failures, cardiovascular illnesses, and other conditions are becoming increasingly common as a result of the rising prevalence of chronic diseases. This is a significant factor driving organ care product demand. Cirrhosis is the eleventh largest cause of death globally, and liver cancer is the sixteenth leading cause of death, according to the European Association for the Study of Liver.
However, limitations, such as a scarcity of organ donors for transplantation and high costs, are projected to limit market expansion. The need for organ care is being hampered by the high expense of therapy. The lengthy clearance process for novel organ care products hinders the organ care market's growth. The market's expansion is being hampered by a scarcity of trained specialists in the organ care system. Transplanting a human organ is a very sophisticated surgery requiring outstanding abilities. Because there are so few surgeons in this field who can perform these types of procedures, the cost of this procedure is extremely high. This aspect can potentially stifle the expansion of the organ transplantation market significantly. Furthermore, the number of organ donors is insignificant compared to the number of persons who require such organs. Another key aspect that may stymie the expansion of the organ transplantation market is the rising incidence of organ failure.
Key Developments
In December 2021, Penn Medicine announced that it had received a seven-year, $14 million grant from the National Institutes of Health (NIH) to apply chimeric antigen receptor T-cell immunotherapies to identify and treat patients in need of kidney transplants. OrganOx Limited debuted its ground-breaking liver perfusion equipment in January 2019. It was also given the green light by the UK's National Institute for Health and Care Excellence.
By product type, the global organ transplant market can be segmented into organ preservation solutions, transplant diagnostics, tissue products, and others.
The tissue products category is expected to dominate the market. The segment's growth is fueled by rising demand for transplant operations such as cochlear implants, orthopedic soft tissues, heart valves, and bone marrow.
By organ type, the global organ transplant market can be segmented into heart, intestine, kidney, liver, lung, and pancreas.
Renal or kidney transplantation is the most prevalent type of organ transplantation worldwide. Although various treatments for end-stage renal disease, such as dialysis, are available, kidney transplantation is widely regarded as the best option.
By end-users, the global organ transplant market can be segmented into transplant centers, hospitals, and others.
The hospital's category accounted for the greatest proportion owing to the significant number of organ and tissue transplant procedures performed at hospitals. However, due to the rising demand for healthcare facilities that cater to patients' unmet requirements and government programs encouraging organ donation, the transplant centers category is likely to increase over the projection period.
By geography, the global organ transplant market can be segmented into the Asia Pacific, North America, the Middle East and Africa, South America, and Europe.
Over the projected period, the Asia Pacific region is expected to grow at the highest rate. The developing medical tourism in Asia Pacific countries such as India, the growing geriatric population in various nations, and the rising prevalence of congenital hydrocephalus in China are all factors driving revenue growth in this regional market.
COVID-19 Insights
Access to solid organ transplantation has been hampered by the COVID-19 epidemic. During the epidemic, the number of transplants performed decreased globally. The most afflicted organ transplants were kidneys, followed by the lungs, liver, and heart. COVID-19 had a global impact on transplantation, with a 31% decline in solid organ transplants conducted during the first pandemic wave compared to the previous year. Approximately 48,000 years of patient life were lost as a result of this deterioration.
Market Segmentation:
By Product Type
- Organ preservation solutions
- Transplant diagnostics
- Tissue products
- Others
By Organ Type
- Heart
- Intestine
- Kidney
- Liver
- Lung
- Pancreas
By End-Users
- Hospitals
- Transplant Centers
- Others
By Geography
- North America
- USA
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Others
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Middle East and Africa
- Saudi Arabia
- Israel
- Others
- Asia Pacific
- China
- Japan
- India
- South Korea
- Indonesia
- Thailand
- Taiwan
- Others
Table of Contents
1. INTRODUCTION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
5. GLOBAL ORGAN TRANSPLANT MARKET, BY PRODUCT TYPE
6. GLOBAL ORGAN TRANSPLANT MARKET, BY ORGAN TYPE
7. GLOBAL ORGAN TRANSPLANT MARKET, BY END-USERS
8. GLOBAL ORGAN TRANSPLANT MARKET, BY GEOGRAPHY
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
10. COMPANY PROFILES
Companies Mentioned
- OrganOx Limited
- GlaxoSmithKline Plc.
- Pfizer
- Organ Assist B.V.
- Paragonix Technologies Inc.
- Novartis AG
- Preservation Solution Inc.
- Water Medical System LLC
- Sanofi S.A
- XVIVO Perfusion AB
- Bridge to Life Ltd.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | April 2022 |
| Forecast Period | 2020 - 2027 |
| Estimated Market Value ( USD | $ 18.99 billion |
| Forecasted Market Value ( USD | $ 33.63 billion |
| Compound Annual Growth Rate | 8.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
